Page last updated: 2024-10-24

sympathetic neuron axon guidance

Definition

Target type: biologicalprocess

The chemotaxis process that directs the migration of a sympathetic neuron axon growth cone to a specific target site in response to a combination of attractive and repulsive cues. [GOC:BHF, GOC:rl, PMID:22790009]

Sympathetic neuron axon guidance is a complex and intricate process that directs the growth of axons, the long projections of nerve cells, from the sympathetic ganglia, clusters of nerve cell bodies, to their target organs. This process ensures the proper connection of the sympathetic nervous system, which controls various involuntary functions like heart rate, blood pressure, and digestion.

The journey of a sympathetic neuron axon begins in the sympathetic ganglia located along the spinal cord. From here, axons navigate through a complex environment, guided by a series of cues, to reach their target organs, such as the heart, lungs, and blood vessels.

Several key molecular mechanisms contribute to sympathetic neuron axon guidance:

1. **Chemoattraction and Chemorepulsion:** Axons are attracted by specific chemicals (chemoattractants) and repelled by others (chemorepellants) in the environment. These cues are often secreted from target organs, guiding axons towards their destinations.

2. **Axon-Glia Interactions:** Glial cells, non-neuronal cells that support and protect neurons, play a crucial role in axon guidance. Schwann cells, the glial cells of the peripheral nervous system, provide a supportive scaffold for axons and secrete molecules that influence their direction.

3. **Extracellular Matrix Components:** The extracellular matrix (ECM), a network of molecules surrounding cells, provides a structural framework and contains molecules like laminin and collagen that can influence axon growth.

4. **Growth Cone Navigation:** The tip of a growing axon is called a growth cone, and it contains specialized structures called filopodia and lamellipodia, which sense the environment and direct the axon's path. Growth cones use these structures to navigate towards attractants and away from repellants, choosing the optimal route to the target.

5. **Axon-Axon Interactions:** Axons can also interact with each other, forming bundles called fascicles. This fasciculation can help to guide axons along a specific pathway, promoting coordinated growth.

The specific cues and pathways used during sympathetic neuron axon guidance vary depending on the target organ and the developmental stage. However, the general principles of chemoattraction, chemorepulsion, and growth cone navigation are essential to this process.

Defects in sympathetic neuron axon guidance can lead to various neurological disorders, including autonomic neuropathy, which affects the function of the sympathetic nervous system, and congenital malformations involving the heart, lungs, and other organs.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Endothelin-converting enzyme 1An endothelin-converting enzyme 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P42892]Homo sapiens (human)
Endothelin-1 receptorAn endothelin-1 receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25101]Homo sapiens (human)

Compounds (52)

CompoundDefinitionClassesRoles
amiodaroneamiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound
cardiovascular drug
thiorphanThiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.N-acyl-amino acid
avaproirbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
azaspiro compound;
biphenylyltetrazole
angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
mianserinmianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.

Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
propranololpropranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
naphthalenes;
propanolamine;
secondary amine
anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
sulfathiazolesulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.

Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.
1,3-thiazoles;
substituted aniline;
sulfonamide;
sulfonamide antibiotic
antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfisoxazolesulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.

Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
isoxazoles;
sulfonamide;
sulfonamide antibiotic
antibacterial drug;
drug allergen
captoprilcaptopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.

Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
bosentan anhydrousBosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.primary alcohol;
pyrimidines;
sulfonamide
antihypertensive agent;
endothelin receptor antagonist
1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)-1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-: an ET(A) and ET(B) endothelin receptor antagonist; structure in first source
ro 46-2005Ro 46-2005: an orally active non-peptide antagonist of endothelin receptors; structure given in first source
pd 142893PD 142893: functional antagonist of endothelin-stimulated vasoconstriction
5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide: structure in first source; endothelin receptor antagonistnaphthalenes;
sulfonic acid derivative
tak 044TAK 044: endothelin receptor antagonist
endothelin (16-21)endothelin (16-21): C-terminal hexapeptide of endothelin; amino acid seq. given in first sourcepeptide
2-(4-morpholinyl)-4h-1-benzopyran-4-one2-(4-morpholinyl)-4H-1-benzopyran-4-one: an aminochromone; exhibits both antiproliferative and antichemotactic activity in vitro
cgs 26303CGS 26303: a potent non-peptidic inhibitor of neutral endopeptidase capable of protecting atrial natriuretic peptide from enzymatic degradation; structure given in first source
tezosentantezosentan: structure in first source
bms 207940N-((2'-(((4,5-dimethyl-3-isoxazolyl)amino)sulfonyl)-4-(2-oxazolyl)(1,1'-biphenyl)-2-yl)methyl)-N,3,3-trimethylbutanamide: an ET(A) receptor antagonist; structure in first source
atrasentanAtrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.pyrrolidines
lu 135252
enrasentanenrasentan : A member of the class of indanes that is 2,3-dihydro-1H-indene which is substituted by a 1,3-benzodioxol-5-yl group, carboxy group, 2-(2-hydroxyethoxy)-4-methoxyphenyl group and a propoxy group at positions 1S, 2R, 3S and 5, respectively. It is an orally active mixed endothelin A/B receptor antagonist with a 100-fold greater affinity for the endothelin A receptor. The drug was being developed by GSK for the treatment of congestive heart failure and pulmonary hypertension (clinical trials discontinued).

enrasentan: decreases ischemic brain injury; an endothelin A and B receptor antagonist; structure in first source
aromatic ether;
benzodioxoles;
indanes;
monocarboxylic acid;
monomethoxybenzene;
primary alcohol
antihypertensive agent;
endothelin receptor antagonist
2-[(4,6-dimethyl-2-pyrimidinyl)oxy]-3-methoxy-3,3-diphenylpropanoic aciddiarylmethane
tbc-11251sitaxsentan: endothelin A receptor antagonist; structure in first sourcebenzodioxoles
bq 123cyclo(Trp-Asp-Pro-Val-Leu): derived from the modification of a natural lead of BE-18257B, an endothelin A receptor antagonist; has neuroprotective activity; amino acid sequence given in first sourcecyclic peptide
phosphoramidonphosphoramidon : A dipeptide isolated from the cultures of Streptomyces tanashiensis.

phosphoramidon: a membrane metallo-endopeptidase & endothelin-converting enzyme inhibitor; thermolysin inhibitor from culture filtrate of Streptomyces tanashiensis; structure
deoxyaldohexose phosphate;
dipeptide
bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
a 192621A 192621: ET(B) receptor antagonist
benzyloxycarbonyl-phe-ala-fluormethylketonecathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).
irl 2500IRL 2500: Endothelin-B receptor antagonist; structure in first source
ro 46-8443Ro 46-8443: a non-peptide endothelin ET(B) receptor selective antagonist; structure given in first source
sulindac sulfonesulindac sulfone : A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.

sulindac sulfone: inhibits K-ras-dependent cyclooxygenase-2; sulfated analog of indomethacin;; CP248 is an antineoplastic agent that fosters microtubule depolymerization; structure in first source
monocarboxylic acid;
organofluorine compound;
sulfone
apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ro 47-8634Ro 47-8634: structure in first source
clazosentanclazosentan: endothelin A receptor antagonist used for cerebral vasospasm; structure in first source;
lu 224332felotaxel: an antineoplastic agent; structure in first source
lu 208075ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertensiondiarylmethane
bms 193884
cgs 35066CGS 35066: an endothelin-converting enzyme-1 inhibitor; structure in first source
ci 1020
lu 302872LU 224332: endothelin-A/B receptor antagonist
bms 248360
zibotentanZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferationphenylpyridine
avosentanAvosentan: structure in first source
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride
s 3304S 3304: structure in first source
naluzotannaluzotan: an antidepressant and anti-anxiety agent; structure in first source
macitentanaromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides
antihypertensive agent;
endothelin receptor antagonist;
orphan drug
a 803467A 803467: an Nav1.8 sodium channel blocker; structure in first source
endothelin-1Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)
pd 156707
act-132577ACT-132577 : A member of the class of sulfamides in which one of the amino groups of sulfonamide is substituted by a 5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl group. An active metabolite of macitentan (obtained by oxidative depropylation), an orphan drug used for the treatment of pulmonary arterial hypertension.

aprocitentan: a macitentan metabolite
aromatic ether;
organobromine compound;
pyrimidines;
sulfamides
antihypertensive agent;
drug metabolite;
endothelin receptor antagonist;
xenobiotic metabolite
endothelins
nitd 609NITD 609: an antimalarial and coccidiostat; structure in first source